The main area of research in medical retina has been neovascular macular degeneration. Addenbrooke’s was a site for the national PDT cohort study which investigated verteporfin photodynamic therapy. We are currently a site for the IVAN study which is assessing the relative efficacy of ranibizumab and bevacizumab and the relative effectiveness of two different anti-VEGF treatment regimens.
The medical retina service is headed by Mr Douglas Newman and Mr Jong Ong. They are planning to be involved in future clinical research studies assessing new therapeutic agents in the treatment of neovascular macular degeneration, diabetic macular oedema and retinal vein occlusion. Any suggestions for clinical research projects are always welcome from trainees.